Immunotherapy in nonmuscle invasive bladder cancer: current and emerging treatments

Research output: Contribution to journalArticle

Abstract

PURPOSE OF REVIEW: There is a significant unmet need for efficacious second-line treatment options for patients who have failed bacillus Calmette-Guerin (BCG) therapy for nonmuscle invasive urothelial carcinoma (NMIBC). Recent advances in our understanding of systemic immunotherapy have transformed the management of advanced urothelial carcinoma and have led to the development of multiple novel agents. Using this insight, these agents are now being investigated for use in NMIBC. RECENT FINDINGS: Although BCG has been used to treat high-risk NMIBC for decades, new applications of immunotherapy include the use of exogenous cytokines to boost immune response, vaccines to activate the immune system against specific tumor-associated antigens, intravesical agents that cause generalized local inflammation, and targeted antibodies against proteins on the surface of immune checkpoint inhibitors. Although most of these agents are still being investigated in clinical trials and are not yet considered standard of care, they hold significant promise in the treatment of patients with high-risk NMIBC. SUMMARY: The use of immunotherapy has significantly improved survival outcomes in advanced urothelial carcinoma. Based on rapid advances in our understanding of the immune system and tumor biology, these agents are also poised to alter the therapeutic landscape for NMIBC dramatically as clinical trials are completed.

Original languageEnglish (US)
Pages (from-to)183-187
Number of pages5
JournalCurrent opinion in oncology
Volume31
Issue number3
DOIs
StatePublished - May 1 2019

Fingerprint

Urinary Bladder Neoplasms
Immunotherapy
Mycobacterium bovis
Carcinoma
Immune System
Clinical Trials
Systems Biology
Neoplasm Antigens
Therapeutics
Standard of Care
Membrane Proteins
Vaccines
Cytokines
Inflammation
Survival
Antibodies
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Immunotherapy in nonmuscle invasive bladder cancer : current and emerging treatments. / Gupta, Mohit; Kates, Max; Bivalacqua, Trinity.

In: Current opinion in oncology, Vol. 31, No. 3, 01.05.2019, p. 183-187.

Research output: Contribution to journalArticle

@article{1e50a203c67d4ae6b843dcd30dcabc07,
title = "Immunotherapy in nonmuscle invasive bladder cancer: current and emerging treatments",
abstract = "PURPOSE OF REVIEW: There is a significant unmet need for efficacious second-line treatment options for patients who have failed bacillus Calmette-Guerin (BCG) therapy for nonmuscle invasive urothelial carcinoma (NMIBC). Recent advances in our understanding of systemic immunotherapy have transformed the management of advanced urothelial carcinoma and have led to the development of multiple novel agents. Using this insight, these agents are now being investigated for use in NMIBC. RECENT FINDINGS: Although BCG has been used to treat high-risk NMIBC for decades, new applications of immunotherapy include the use of exogenous cytokines to boost immune response, vaccines to activate the immune system against specific tumor-associated antigens, intravesical agents that cause generalized local inflammation, and targeted antibodies against proteins on the surface of immune checkpoint inhibitors. Although most of these agents are still being investigated in clinical trials and are not yet considered standard of care, they hold significant promise in the treatment of patients with high-risk NMIBC. SUMMARY: The use of immunotherapy has significantly improved survival outcomes in advanced urothelial carcinoma. Based on rapid advances in our understanding of the immune system and tumor biology, these agents are also poised to alter the therapeutic landscape for NMIBC dramatically as clinical trials are completed.",
author = "Mohit Gupta and Max Kates and Trinity Bivalacqua",
year = "2019",
month = "5",
day = "1",
doi = "10.1097/CCO.0000000000000533",
language = "English (US)",
volume = "31",
pages = "183--187",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Immunotherapy in nonmuscle invasive bladder cancer

T2 - current and emerging treatments

AU - Gupta, Mohit

AU - Kates, Max

AU - Bivalacqua, Trinity

PY - 2019/5/1

Y1 - 2019/5/1

N2 - PURPOSE OF REVIEW: There is a significant unmet need for efficacious second-line treatment options for patients who have failed bacillus Calmette-Guerin (BCG) therapy for nonmuscle invasive urothelial carcinoma (NMIBC). Recent advances in our understanding of systemic immunotherapy have transformed the management of advanced urothelial carcinoma and have led to the development of multiple novel agents. Using this insight, these agents are now being investigated for use in NMIBC. RECENT FINDINGS: Although BCG has been used to treat high-risk NMIBC for decades, new applications of immunotherapy include the use of exogenous cytokines to boost immune response, vaccines to activate the immune system against specific tumor-associated antigens, intravesical agents that cause generalized local inflammation, and targeted antibodies against proteins on the surface of immune checkpoint inhibitors. Although most of these agents are still being investigated in clinical trials and are not yet considered standard of care, they hold significant promise in the treatment of patients with high-risk NMIBC. SUMMARY: The use of immunotherapy has significantly improved survival outcomes in advanced urothelial carcinoma. Based on rapid advances in our understanding of the immune system and tumor biology, these agents are also poised to alter the therapeutic landscape for NMIBC dramatically as clinical trials are completed.

AB - PURPOSE OF REVIEW: There is a significant unmet need for efficacious second-line treatment options for patients who have failed bacillus Calmette-Guerin (BCG) therapy for nonmuscle invasive urothelial carcinoma (NMIBC). Recent advances in our understanding of systemic immunotherapy have transformed the management of advanced urothelial carcinoma and have led to the development of multiple novel agents. Using this insight, these agents are now being investigated for use in NMIBC. RECENT FINDINGS: Although BCG has been used to treat high-risk NMIBC for decades, new applications of immunotherapy include the use of exogenous cytokines to boost immune response, vaccines to activate the immune system against specific tumor-associated antigens, intravesical agents that cause generalized local inflammation, and targeted antibodies against proteins on the surface of immune checkpoint inhibitors. Although most of these agents are still being investigated in clinical trials and are not yet considered standard of care, they hold significant promise in the treatment of patients with high-risk NMIBC. SUMMARY: The use of immunotherapy has significantly improved survival outcomes in advanced urothelial carcinoma. Based on rapid advances in our understanding of the immune system and tumor biology, these agents are also poised to alter the therapeutic landscape for NMIBC dramatically as clinical trials are completed.

UR - http://www.scopus.com/inward/record.url?scp=85064886081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064886081&partnerID=8YFLogxK

U2 - 10.1097/CCO.0000000000000533

DO - 10.1097/CCO.0000000000000533

M3 - Article

C2 - 30893148

AN - SCOPUS:85064886081

VL - 31

SP - 183

EP - 187

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 3

ER -